Y-mAbs Therapeutics Inc (NAS:YMAB)
$ 12.06 0.09 (0.75%) Market Cap: 529.23 Mil Enterprise Value: 452.46 Mil PE Ratio: 0 PB Ratio: 5.31 GF Score: 56/100

Q3 2022 Y-mAbs Therapeutics Inc Earnings Call Transcript

Nov 08, 2022 / 09:00PM GMT
Release Date Price: $3.89 (+16.12%)
Operator

Good afternoon, and welcome to the Y-mAbs Therapeutics, Inc. Earnings Conference Call for the Third Quarter of 2022. (Operator Instructions) As a reminder, today's conference will be recorded.

Let me quickly remind you that the following discussion contains certain statements that are considered forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995.

Such statements include, but are not limited to, statements about our business model and development, commercialization and product distribution plans, current and future clinical and preclinical studies in our research and development programs; expectations related to the timing of the initiation and completion of the regulatory submissions, regulatory marketing and reimbursement approvals, including statements with respect to the potential FDA approval and utility of omburtamab pipeline development programs, potential for DANYELZA territory expansion and advancement of SADA, collaborations or strategic partnerships and the potential benefits thereof; expectations related to our anticipated cash runway

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot